
Organic Process Research and Development p. 336 - 345 (2017)
Update date:2022-07-31
Topics:
Goundry, William R. F.
Boardman, Kay
Cunningham, Oliver
Evans, Matthew
Jones, Martin F.
Millard, Kirsty
Rozada-Sanchez, Raquel
Sawyer, Yvonne
Siedlecki, Paul
Whitlock, Brian
Recently, the aminoquinazoline motif has been highly prevalent in anticancer pharmaceutical compounds. Synthetic methods are required to make this structure on a multikilo scale and in high purity. The initial route to aminoquinazoline AZD8931 suffered from the formation of late-stage impurities. To avoid these impurities, a new high-yielding Dimroth rearrangement approach to the aminoquinazoline core of AZD8931 was developed. Assessment of route options on a gram scale demonstrated that the Dimroth rearrangement is a viable approach. The processes were then evolved for large-scale production with learning from a kilo campaign and two plant-scale manufactures. Identification of key process impurities offers an insight into the mechanisms of the Dimroth rearrangement as well as the hydrogenation of a key intermediate. The final processes were operated on a 30 kg scale delivering the target AZD8931 in 41% overall yield.
Contact:+ 86 512 52491118
Address:1 Fuyu Road, Haiyu TownChangshu, Jiangsu, China
Shanghai Micro-mega Industry Co., Ltd.
Contact:0086-21-34628682;57153848
Address:Rm413,No.413,West Meilong Road, Minhang District,Shanghai P R China
ZHEJIANG JIANYE CHEMICAL CO.,LTD.
Contact:86-571-64149273,64149234
Address:No. 48, Fuxi Road, Meicheng Town
Nanjing Legend Pharmaceutical & Chemical Co., Ltd.
Contact:+86-25-83767696
Address:14-7 Zhongshan Lu Guluo District, Nanjing
Nanjing Samwon International Limited
Contact:+86-25-84873444
Address:1108, BLDG B, New Century Plaza, No 1, South Taiping Rd.,
Doi:10.1021/ja00191a036
(1989)Doi:10.1016/j.carres.2009.08.028
(2009)Doi:10.1016/j.jfluchem.2005.02.020
(2005)Doi:10.1002/anie.200903558
(2009)Doi:10.1021/acsmedchemlett.7b00296
(2017)Doi:10.1246/cl.1988.1639
(1988)